KRAS and lung adenocarcinoma: Abnormal activation of the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway and impaired IFN-I innate immune response have been identified as factors determining the susceptibility of KRAS-mutant lung adenocarcinoma cells to CVB3-induced cytotoxicity [24].